Peng Wang, Ph.D.

As a Global Technical Specialist, I lead the technical strategy and customer engagement for Lonza’s advanced therapeutic platforms, including viral vectors (AAV, LV, and other gene delivery systems) and RNA/LNP technologies. My role focuses on: • Platform Expertise: Driving innovation and technical excellence across viral vector and RNA/LNP platforms to support gene therapy, cell therapy, and mRNA-based therapeutics. • Customer Solutions: Partnering with global clients to design and implement scalable, regulatory-compliant manufacturing solutions tailored to their program needs. • Cross-Functional Leadership: Collaborating with R&D, process development, and commercial teams to align technical capabilities with market demands and emerging trends. • Thought Leadership: Representing Lonza at industry conferences, sharing insights on platform advancements, and guiding customers through complex technical challenges. This position combines deep scientific knowledge with strategic business development, ensuring that Lonza remains a trusted partner for next-generation therapies.

Platform Technology Development and Implementation • Xcite® AAV Platform Technology – Suspension Transient Transfection and Producer Cell Line • Xcite® Lenti Platform Technology – Suspension Transient Transfection and Producer Cell Line

Manage a portfolio of collaborative projects with cross-functional teams from different sites and companies. • Initiated and managed collaborative innovation projects and developed work plans and budgets for internal and external innovation to overcome process development challenges. • Established workflow to implement Biologics platforms for cell and gene therapy. Managed cross-functional teams from multiple divisions to transfer, implement, and evaluate the analytics and producer cell line workflows. Manage R&D resources to support Process Development, Business Development, Marketing, Regulatory Affairs, and Strategic Growth Initiatives and Engineering (SGIE). • Prepared workshops for regulatory agencies and assessed the evolving Cell and Gene Therapy regulatory landscape. • Developed proposals for new clients and existing clients with new modalities. • Designed and implemented novel processes to support the Process Development team. • Prepared webinars and represented Lonza at conferences to support the Marketing team. • Managed and worked with the SGIE team for the second R&D Laboratory Design & Buildout. Directed and oversaw Analytical Team for analytical platform development to support AAV, Lenti, and Exosome producer cell line development. • Designed and implemented AAV, Lenti, and Exosome analytical platforms for potency, content, residual, and vector characterization. • Designed and implemented HTP automation to support process development and producer cell line development. • Evaluated and implemented next-generation tools and approaches for the producer cell lines. Manage the implementation of novel process development for AAV, Lenti, and Exosome projects. • Designed and Implemented miniature bioreactor arrays to optimize upstream processing. • Designed and Implemented miniature resin/buffer screen method to optimize downstream processing. • Designed new purification chemistry/units to overcome the challenges in viral vector downstream processing.

Analytical platform development for AAV quantitative and qualitative analysis. • Developed analytical platforms for AAV full/partial/empty capsid analysis • Evaluated currently available technologies for AAV full/partial/empty capsid analysis such as AUC, TEM, HPLC, MassP, CDMS, et al. • Generated a library of AAV full and empty internal standards such as AAV1, AAV2, AAV5, AAV6, AAV8, AAV9 et al. • Implemented analytical platforms to support both upstream and downstream process development. • Implemented automation to increase throughput for AAV quantitative and qualitative analysis.

Analytical platform development for AAV quantitative and qualitative analysis. • Advanced analytical development for AAV quantitative and qualitative measurement • Lead the analytical support for the Producer Cell Line Development • Lead the first R&D Laboratory Design & Buildout as Subject-matter expert

Supporting the BP commission to provide non-mandatory guidance to cell and gene therapy developers.

Biomarker discovery for triple-negative breast cancer by integration of Proteomics and Metabolomics. Publication • "Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple-negative breast cancer"

Natural product discovery and biosynthesis in the microbiome. Publication • "Glutamic acid is a carrier for hydrazine during the biosyntheses of fosfazinomycin and kinamycin" • "Heteroatom–heteroatom bond formation in natural product biosynthesis" • "Production of stealthin C involves an S–N-type Smiles rearrangement" • "The cremeomycin biosynthetic gene cluster encodes a pathway for diazo formation"

Engineering biosynthesis for new generation Antibiotics Publication • "Uncovering the enzymes that catalyze the final steps in oxytetracycline biosynthesis" • "Heterologous expression and manipulation of three tetracycline biosynthetic pathways" • "C-glycosylation of anhydrotetracycline scaffold with SsfS6 from the SF2575 biosynthetic pathway" • "Cyclization of fungal nonribosomal peptides by a terminal condensation-like domain" • "Complexity generation during natural product biosynthesis using redox enzymes" • "Discovery and characterization of a group of fungal polycyclic polyketide prenyltransferases" • "Genetic characterization of enzymes involved in the priming steps of oxytetracycline biosynthesis in Streptomyces rimosus" • "Characterization of a novel tetracycline tailoring pathway in SF2575 biosynthesis" • "Fungal Indole Alkaloid Biosynthesis: Genetic and Biochemical Investigation of the Tryptoquialanine Pathway in Penicillium aethiopicum" ...and more